The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1350
November 1, 2010
View Complete Issue         Table of Contents 2019 
Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
November 1, 2010 (Issue: 1350)
The FDA has approved a new 550-mg tablet of rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic, to reduce the risk of recurrent hepatic encephalopathy (HE). A 200-mg tablet has been available for treatment of travelers’ diarrhea...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
Article code: 1350c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.